HFA Premium Access

Omecamtiv Mecarbil in Patients with Severe Heart Failure: An Analysis from Global Approach to Lowering Adverse Cardiac Outcomes through Improving Contractility in Heart Failure (GALACTIC-HF)

Congress Presentation

About the speaker

Professor G Michael Felker

Duke University Medical Center, Durham (United States of America)
14 presentations
0 follower

13 more presentations in this session

Association of Baseline Cardiac Biomarkers on Clinical Outcomes and Vericiguat Treatment Effect in Heart Failure with Reduced Ejection Fraction: Insights from the VICTORIA Trial

Speaker: Associate Professor C. DeFilippi (Baltimore, US)


Efficacy and Safety of Antithrombotic Strategies in Patients With Atrial Fibrillation and Recent ACS or PCI With and Without A History of Heart Failure: Insights From the AUGUSTUS Trial

Speaker: Doctor M. Fudim (Durham, US)


Nurse Intervention for Less Chronic Heart Failure Study

Speaker: Professor S. Stewart (Adelaide, AU)


Efficacy of omecamtiv mecarbil in heart failure with reduced ejection fraction according to N-terminal pro-B-type natriuretic peptide level: Insights from the GALACTIC-HF trial.

Speaker: Professor J. McMurray (Glasgow, GB)


Telemedical Interventional Management in Heart Failure

Speaker: Professor F. Koehler (Berlin, DE)


Access the full session

Clinical Trial Updates

Speakers: Professor G. Felker, Associate Professor C. DeFilippi, Doctor M. Fudim, Professor S. Stewart, Professor J. McMurray...

About the event


Heart Failure 2021

29 June - 1 July 2021

Sessions Presentations

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb